Business, energy, technology, markets and global industry news from Business News Today

durvalumab

PharmaDeviceNews durvalumab
Pharma & Biotech

AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer

Imfinzi has FDA approval with BCG in early high-risk bladder cancer. The next test is adoption, recurrence data and real-world use.

Read More
Representative image: AstraZeneca’s Imfinzi approval with BCG brings immunotherapy into earlier bladder cancer care, reshaping treatment options for high-risk non-muscle-invasive bladder cancer.
Pharma & Biotech

Imfinzi approval gives AstraZeneca a first immunotherapy combination in early bladder cancer

Imfinzi moves into early bladder cancer, but can AstraZeneca turn a DFS win into real-world bladder-preserving impact?

Read More
Pharma & Biotech

Why AstraZeneca’s EMERALD-3 and SERENA-6 data could influence future standards of cancer care

Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.

Read More
Representative image of an oncology consultation as Imfinzi moves toward becoming the first NHS immunotherapy option for eligible stomach cancer patients in England, marking a potential shift in gastric cancer treatment pathways.
Pharma & Biotech

AstraZeneca’s Imfinzi becomes first NHS immunotherapy for operable stomach cancer

Stomach cancer care gains immunotherapy, but NHS adoption now depends on surgery timing, toxicity management and recurrence data.

Read More
Representative image of lung cancer immunotherapy research as Innate Pharma advances IPH5201 in the MATISSE Phase 2 trial for resectable non-small cell lung cancer at AACR 2026.
Pharma & Biotech

Is CD39 finally ready for a breakout moment in lung cancer? Innate Pharma tests the thesis

Innate Pharma’s IPH5201 posted encouraging Phase 2 lung cancer data at AACR 2026. Read what it could change for perioperative NSCLC treatment.

Read More
Pharma & Biotech

Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?

Can Ampligen’s Phase 3 push reshape pancreatic cancer treatment? Read how AIM ImmunoTech’s latest clinical progress could change the oncology outlook.

Read More
Pharma & Biotech

Can Ampligen plus durvalumab finally overcome immunotherapy resistance in metastatic pancreatic cancer

Explore what AIM ImmunoTech’s Ampligen Phase 2 data could change for pancreatic cancer immunotherapy and what risks still remain.

Read More